Otsuka patent expiration
1. Abilify patent expiration
ABILIFY's oppositions filed in EPO
ABILIFY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 11 months ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 11 months ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5006528 | OTSUKA | Carbostyril derivatives |
Oct, 2014
(9 years ago) | |
|
US5006528 (Pediatric) | OTSUKA | Carbostyril derivatives |
Apr, 2015
(9 years ago) | |
| US9358207 | OTSUKA | Flashmelt oral dosage formulation |
Apr, 2020
(4 years ago) | |
| US8518421 | OTSUKA | Flashmelt oral dosage formulation |
Jan, 2021
(3 years ago) | |
|
US8518421 (Pediatric) | OTSUKA | Flashmelt oral dosage formulation |
Jul, 2021
(3 years ago) | |
| US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(2 years ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(2 years ago) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(2 years ago) | |
| US6977257 | OTSUKA | Aripiprazole oral solution |
Apr, 2022
(2 years ago) | |
|
US8642600 (Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(2 years ago) | |
|
US6977257 (Pediatric) | OTSUKA | Aripiprazole oral solution |
Oct, 2022
(1 year, 10 months ago) | |
|
US8642760 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(1 year, 5 months ago) | |
|
US8580796 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(1 year, 5 months ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(8 months ago) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(2 months ago) | |
| US7550445 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(a month ago) | |
| US7115587 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(a month ago) | |
|
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(3 months from now) | |
|
US7115587 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(4 months from now) | |
|
US7550445 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(4 months from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(1 year, 10 months from now) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| New Indication(I-616) | Nov 19, 2012 |
| New Indication(I-633) | Feb 16, 2014 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Treatment: Treatment of schizophrenia including maintaining stability in patients with schizophrenia; Treatment of irritability associated with autistic disorder; Treatment of major depressive disorder (mdd); Tr...
Dosage: TABLET; TABLET, ORALLY DISINTEGRATING; SOLUTION; INJECTABLE
How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage
ABILIFY family patents
2. Abilify Asimtufii patent expiration
ABILIFY ASIMTUFII's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8399469 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759351 | OTSUKA | Methods for administering aripiprazole |
Aug, 2023
(1 year, 1 month ago) | |
| US8338428 | OTSUKA | Methods for administering aripiprazole |
Aug, 2023
(1 year, 1 month ago) | |
| US8338427 | OTSUKA | Methods for administering aripiprazole |
Mar, 2025
(6 months from now) | |
| US11638757 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
| US11097007 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
| US10517951 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 27 April, 2023
Treatment: Use of aripiprazole in extended release injectable suspension; Maintenance monotherapy treatment of bipolar i disorder
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ABILIFY ASIMTUFII family patents
3. Abilify Mycite Kit patent
expiration
ABILIFY MYCITE KIT's oppositions filed in EPO
ABILIFY MYCITE KIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 11 months ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 11 months ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(2 years ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(2 years ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(8 months ago) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(2 months ago) | |
| US11476952 | OTSUKA | Pharma-informatics system |
Apr, 2026
(1 year, 7 months from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(1 year, 10 months from now) | |
| US7978064 | OTSUKA | Communication system with partial power source |
Sep, 2026
(2 years from now) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(2 years from now) | |
| US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(3 years from now) | |
| US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(4 years from now) | |
| US9060708 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(4 years from now) | |
| US9258035 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(4 years from now) | |
| US8674825 | OTSUKA | Pharma-informatics system |
Apr, 2029
(4 years from now) | |
| US8956288 | OTSUKA | In-body power source having high surface area electrode |
Jul, 2029
(4 years from now) | |
| US10441194 | OTSUKA | Ingestible event marker systems |
Jul, 2029
(4 years from now) | |
| US8945005 | OTSUKA | Controlled activation ingestible identifier |
Aug, 2029
(4 years from now) | |
| US9433371 | OTSUKA | In-body device with virtual dipole signal amplification |
Sep, 2029
(5 years from now) | |
| US8718193 | OTSUKA | Active signal processing personal health signal receivers |
Dec, 2029
(5 years from now) | |
| US9149577 | OTSUKA | Body-associated receiver and method |
Dec, 2029
(5 years from now) | |
| US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(5 years from now) | |
| US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(5 years from now) | |
| US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(5 years from now) | |
| US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(6 years from now) | |
| US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(6 years from now) | |
| US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(6 years from now) | |
| US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(6 years from now) | |
| US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(6 years from now) | |
| US11229378 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jul, 2031
(6 years from now) | |
| US9320455 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Dec, 2031
(7 years from now) | |
| US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(7 years from now) | |
| US9577864 | OTSUKA | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
Oct, 2033
(9 years from now) | |
| US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(9 years from now) | |
| US10097388 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(10 years from now) | |
| US9270503 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(10 years from now) | |
| US9787511 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Treatment of schizophrenia; Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Method of using a receiver to ident...
Dosage: TABLET
More Information on Dosage
ABILIFY MYCITE KIT family patents
4. Inqovi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9567363 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(4 years from now) | |
| US8268800 | OTSUKA | Certain compounds, compositions and methods |
Aug, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618075 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(4 years from now) | |
| US11963971 | OTSUKA | Combination decitabine and cedazuridine solid oral dosage forms |
Feb, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2025 |
| Orphan Drug Exclusivity(ODE-316) | Jul 07, 2027 |
Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient
NCE-1 date: 07 July, 2024
Market Authorisation Date: 07 July, 2020
Treatment: Method for inhibiting degradation of a cda substrate by administering cedazuridine
Dosage: TABLET
More Information on Dosage
INQOVI family patents
5. Jynarque patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5972882 | OTSUKA | Treatment of polycystic kidney disease using vasopressin V2 receptor antagonists |
Dec, 2018
(5 years ago) | |
| US5753677 | OTSUKA | Benzoheterocyclic compounds |
May, 2020
(4 years ago) | |
| US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-779) | Apr 23, 2021 |
| Orphan Drug Exclusivity(ODE-178) | Apr 23, 2025 |
Drugs and Companies using TOLVAPTAN ingredient
Market Authorisation Date: 23 April, 2018
Treatment: Treatment of autosomal dominant polycystic kidney disease
Dosage: TABLET
How can I launch a generic of JYNARQUE before it's drug patent expiration?
More Information on Dosage
JYNARQUE family patents
6. Raxar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5563138 | OTSUKA | Benzoheterocyclic compounds |
Oct, 2013
(10 years ago) | |
Drugs and Companies using GREPAFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 06 November, 1997
Treatment: NA
Dosage: TABLET
More Information on Dosage
RAXAR family patents
7. Rexulti patent expiration
REXULTI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7888362 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 6 months from now) | |
| USRE48059 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8349840 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 6 months from now) | |
| US8618109 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 6 months from now) | |
| US9839637 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 6 months from now) | |
|
US8349840 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(2 years from now) | |
|
US8618109 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(2 years from now) | |
|
US7888362 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(2 years from now) | |
|
US9839637 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(2 years from now) | |
|
USRE48059 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Jun, 2029
(4 years from now) | |
| US10307419 | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Oct, 2032
(8 years from now) | |
|
US10307419 (Pediatric) | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-186) | Sep 23, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2020 |
| New Patient Population(NPP) | Dec 27, 2024 |
| New Indication(I-913) | May 10, 2026 |
| Pediatric Exclusivity(PED) | Nov 10, 2026 |
| M(M-14) | May 08, 2027 |
Drugs and Companies using BREXPIPRAZOLE ingredient
NCE-1 date: 10 November, 2025
Market Authorisation Date: 10 July, 2015
Treatment: Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
Dosage: TABLET
How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage
REXULTI family patents
8. Samsca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5258510 | OTSUKA | Benzoheterocyclic compounds |
Nov, 2012
(11 years ago) | |
| US5753677 | OTSUKA | Benzoheterocyclic compounds |
May, 2015
(9 years ago) | |
| US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 19, 2014 |
Drugs and Companies using TOLVAPTAN ingredient
NCE-1 date: 19 May, 2013
Market Authorisation Date: 19 May, 2009
Treatment: Method of treating hyponatremia
Dosage: TABLET
How can I launch a generic of SAMSCA before it's drug patent expiration?
More Information on Dosage
SAMSCA family patents